Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Warfarin pharmacogenetics meets clinical use.

Schwab M, Schaeffeler E.

Blood. 2011 Sep 15;118(11):2938-9. doi: 10.1182/blood-2011-07-367763. No abstract available.

2.

Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplements.

Gage BF, Milligan PE.

Thromb Res. 2005;117(1-2):55-9; discussion 65-7. Epub 2005 Jul 25. Review. No abstract available.

PMID:
16043212
3.

Gene-based warfaring dosing.

Carleton B.

Ther Drug Monit. 2010 Jun;32(3):332. doi: 10.1097/FTD.0b013e3181e1a665. No abstract available.

PMID:
20498559
4.

Pharmacogenomics and warfarin.

Anderson DC Jr.

Am J Health Syst Pharm. 2009 Jan 15;66(2):121. doi: 10.2146/ajhp080635. No abstract available.

PMID:
19139475
5.

Warfarin dose prediction in children using pharmacogenetics information.

Biss T, Hamberg AK, Avery P, Wadelius M, Kamali F.

Br J Haematol. 2012 Oct;159(1):106-9. doi: 10.1111/j.1365-2141.2012.09230.x. Epub 2012 Jul 18. No abstract available.

PMID:
22804567
6.

Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing.

Roper N, Storer B, Bona R, Fang M.

J Mol Diagn. 2010 May;12(3):283-91. doi: 10.2353/jmoldx.2010.090110. Epub 2010 Mar 12.

7.

Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin.

Takahashi H, Echizen H.

Pharmacogenomics J. 2003;3(4):202-14. Review. No abstract available.

PMID:
12931134
8.
9.

Overview of pharmacogenetics in anticoagulation therapy.

Hill CE, Duncan A.

Clin Lab Med. 2008 Dec;28(4):513-24. doi: 10.1016/j.cll.2008.09.002. Review.

PMID:
19059059
10.

CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.

Takahashi H, Wilkinson GR, Padrini R, Echizen H.

Clin Pharmacol Ther. 2004 May;75(5):376-80. Review. No abstract available.

PMID:
15116049
11.

Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation.

Adcock DM, Koftan C, Crisan D, Kiechle FL.

Arch Pathol Lab Med. 2004 Dec;128(12):1360-3.

PMID:
15578879
12.

Warfarin sensitivity and genetic polymorphisms: should pharmacokinetic screening be part of anticoagulant dosing decisions?

Baglin TP.

Clin Adv Hematol Oncol. 2003 Nov;1(11):656-7. No abstract available.

PMID:
16258463
13.

Variant CYP2C9 alleles and warfarin concentrations in patients receiving low-dose versus average-dose warfarin therapy.

Redman AR, Zheng J, Shamsi SA, Huo J, Kelly EJ, Ho RJ, Ritchie DM, Hon YY.

Clin Appl Thromb Hemost. 2008 Jan;14(1):29-37. Epub 2007 Sep 25.

PMID:
17895500
14.

Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery.

Gulseth MP, Grice GR, Dager WE.

Am J Health Syst Pharm. 2009 Jan 15;66(2):123-33. doi: 10.2146/ajhp080127. Review.

PMID:
19139476
15.

Warfarin pharmacogenetics.

Garcia DA, Hylek E.

N Engl J Med. 2009 Jun 4;360(23):2474; author reply 2475. doi: 10.1056/NEJMc090579. No abstract available.

16.

[Application of warfarin pharmacogenetics].

Vasků A.

Vnitr Lek. 2009 Jun;55(6):541. Czech. No abstract available.

PMID:
19662883
17.

Systematic review of pharmacogenetic warfarin dosing.

van Schie RM, Jorgensen AL, de Boer A, Maitland-van der Zee AH; EU-PACT study group.

J Gen Intern Med. 2009 Oct;24(10):1171. doi: 10.1007/s11606-009-1083-9. No abstract available.

18.

Pharmacogenetics of oral anticoagulants.

Daly AK, King BP.

Pharmacogenetics. 2003 May;13(5):247-52. Review.

PMID:
12724615
19.

Warfarin pharmacogenetics.

Shil AB, Strohm MP.

N Engl J Med. 2009 Jun 4;360(23):2474-5; author reply 2475. No abstract available.

PMID:
19504712
20.

Pharmacogenomics and warfarin therapy.

Ndegwa S.

Issues Emerg Health Technol. 2007 Oct;(104):1-8.

PMID:
17912794

Supplemental Content

Support Center